InvestorsHub Logo
Followers 85
Posts 32472
Boards Moderated 86
Alias Born 03/22/2005

Re: None

Sunday, 02/12/2023 7:58:08 PM

Sunday, February 12, 2023 7:58:08 PM

Post# of 29
Qiagen - >>> Strong core growth offsets dwindling COVID-19 demand for Qiagen


February 7, 2023

BERLIN, Feb 7 (Reuters) - Medical diagnostics company Qiagen offset a sharp fall in demand for COVID-19 products at the end of the year with a strong performance in its core businesses, the company said, announcing its full-year and fourth quarter results on Tuesday.

Fourth quarter revenues came in at $498 million, a 14% fall compared with the same period last year. Revenues from COVID products fell 64% to $66 million, but this was offset by strong growth in non-COVID products, where revenues rose 8% to $432 million.

For 2023, the molecular diagnostics test maker expects revenues of $2.05 billion, compared with $2.14 billion for 2022, and an adjusted profit per share of $2.10.

"We have positioned Qiagen well to successfully navigate 2023's volatile macroeconomic environment," said Chief Executive Thierry Bernard.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.